Format

Send to

Choose Destination
Ann Hematol. 2015 Apr;94 Suppl 2:S149-58. doi: 10.1007/s00277-015-2318-y. Epub 2015 Mar 27.

Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.

Author information

1
Service d'Hématologie Adulte, Hôpital Saint-Louis, AP-HP, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France, delphine.rea@sls.aphp.fr.

Abstract

Tyrosine kinase inhibitors (TKIs) targeting the breakpoint cluster region-Abelson 1 (BCR-ABL1) oncoprotein represent an outstanding progress in chronic myeloid leukemia (CML), and long-term survival has become a reality. However, the majority of patients need to be treated during their entire life span; thus, outcome does not solely depend on treatment efficacy but also on how well therapy is tolerated. TKIs have an overall favorable safety profile in clinical practice. Although many patients may encounter adverse events, these usually occur early after treatment initiation, are mild to moderate in intensity and resolve spontaneously, or are easily controlled with adequate supportive care. Whenever treatment interruption is necessary, re-exposition to the same TKI or switch to an alternative TKI is successful in the majority of the cases. However, long-term safety issues have not been fully elucidated at present, especially for new-generation TKIs. Recent evidence has emerged that these new agents may sometimes impinge on vital organs such as the heart and lung in an irreversible fashion especially when comorbidities are present; thus, decision regarding of which TKI should be used must take into account disease-related, TKI-related, and patient-related variables. The purpose of this article is to provide an up-to-date review of common adverse events associated with TKIs and how these events may be optimally managed.

PMID:
25814081
DOI:
10.1007/s00277-015-2318-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center